Drug Information

Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax

Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax

By

What precautions should be taken to prevent tumor lysis syndrome (TLS) in patients receiving venetoclax (Venclexta)?

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

By

In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.

Understanding Biosimilar Drugs

Understanding Biosimilar Drugs

By

There is a lot of talk about biosimilar drugs. What makes a drug a biosimilar?

Cost of TKI Therapy Leads to Delay in Treatment for Many Patients With Leukemia

By

Patients with cancer incur significant out-of-pocket costs before their Medicare drug benefits activate, and due to those costs, many patients with CML delayed starting their treatment.

New Class of Drugs Shows Promise Against Kidney Cancer

New Class of Drugs Shows Promise Against Kidney Cancer

By

A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.

Managing IRAEs in Patients Receiving Checkpoint Inhibitors

Managing IRAEs in Patients Receiving Checkpoint Inhibitors

By

How should side effects of the new checkpoint inhibitor drugs be managed?

Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of Trastuzumab

Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of Trastuzumab

By

Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.

Factors That Determine Sequence of Administration for Multiple Chemotherapeutic Agents

Factors That Determine Sequence of Administration for Multiple Chemotherapeutic Agents

By

Chemotherapy agents are sometimes required to be administered in a specific sequence. What factors influence the need to follow a specific sequence?

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

By

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.

Analysis Shows Better Integration Needed Between ClinicalTrials.gov and Drugs@FDA

Analysis Shows Better Integration Needed Between ClinicalTrials.gov and Drugs@FDA

By

Although Drugs@FDA may be useful for validating trial primary outcomes found on ClinicalTrials.gov, Drugs@FDA lacked information on secondary outcomes and adverse events, including deaths, according to an analysis of data from 100 trials available on both websites.

Widely Prescribed Pain and Anti-inflammation Drug Decreased Cancer Growth

Widely Prescribed Pain and Anti-inflammation Drug Decreased Cancer Growth

By

A widely prescribed pain/anti-inflammatory medication reduced the growth of neurofibromatosis type 2 tumors in mice and in cell cultures, suggesting that the drug could reduce tumor growth in some cancers.

Surrogate End Points Are Poor Predictors of Survival in Cancer Drug Approval

By

US FDA standards demand that surrogate end points used in clinical trials be "reasonably likely to predict" survival for accelerated approval, or be established proxies for survival for traditional approval; however, surrogate end points used frequently lack formal study.

Anticancer Properties of Salicylic Acid and Diflunisal Revealed in Laboratory Experiments

Anticancer Properties of Salicylic Acid and Diflunisal Revealed in Laboratory Experiments

By

Researchers revealed a pathway in cell culture and mice by which salicylic acid decreases inflammation and by which salicylic acid and diflunisal decrease cancerous growth.

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

By

Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.

FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review

FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review

By

The US FDA has granted Priority Review to ofatumumab used in combination with fludarabine and cyclophosphamide for the treatment of chronic lymphocytic leukemia.

Atezolizumab Approved for Locally Advanced or Metastatic Urothelial Carcinoma

Atezolizumab Approved for Locally Advanced or Metastatic Urothelial Carcinoma

By

US FDA granted accelerated approval to atezolizumab (TECENTRIQ), indicated for the treatment of locally advanced or metastatic UC in patients whose disease progressed during or following platinum-based chemotherapy, or in the neoadjuvant or adjuvant setting.

Costs of Orally Administered Cancer Drugs Increased Significantly in Recent Years

Costs of Orally Administered Cancer Drugs Increased Significantly in Recent Years

By

A month of treatment with the newest cancer drugs, based on those introduced in 2014, was 6 times more expensive at launch than cancer drugs introduced in 2000, after adjusting for inflation.

Access to Investigational Drugs (Fact Sheet)

Access to Investigational Drugs (Fact Sheet)

This fact sheet explains investigational drugs and the process by which cancer patients may obtain them.

Ixazomib Improves Progression-Free Survival in Multiple Myeloma

Ixazomib Improves Progression-Free Survival in Multiple Myeloma

Progression-free-survival was improved in all prespecified patient groups, including those with high-risk cytogenetic abnormalities.

Retooled Patient Medication Education in Oncology Improves HCAHPS Survey Scores

Retooled Patient Medication Education in Oncology Improves HCAHPS Survey Scores

By By

Patient responses to the medication questions on the HCAHPS survey demonstrate improved understanding of their medications after implementation of an improved patient education process.

Many Hold Incorrect Beliefs About FDA Approval Standards and Breakthrough Therapies

Many Hold Incorrect Beliefs About FDA Approval Standards and Breakthrough Therapies

By

Recent survey data indicates that the majority of respondents held incorrect beliefs about both U.S. Food and Drug Administration (FDA) approval standards.

Risk of Bladder Cancer Higher for Patients Taking a Specific Diabetes Medication

By

Pioglitazone use correlated with increased rates of bladder cancer across a large population. The risk of developing bladder cancer also increased with higher dose and longer use of the drug.

Immune Therapy Drug Shows Early Promise in Subtype of Endometrial Uterine Cancer

By

In a small group of women with mismatch repair (MMR) deficiency endometrial uterine cancer, survival was increased by pembrolizumab.

Cost-sharing Creates Barrier to Treating Life-threatening Illness

Cost-sharing Creates Barrier to Treating Life-threatening Illness

By

Access to specialty drugs is significantly reduced when insurers require patients to share the high costs of these drugs. Specialty drugs are often the only chance for patients with cancer to achieve long-term survival.

Significant Reduction in Treatment Costs Are Anticipated With the Emergence of Generic TKI

Significant Reduction in Treatment Costs Are Anticipated With the Emergence of Generic TKI

By

With the January 2016 expiration of the patent on Gleevac, significant cost savings can be realized by insurance companies and patients. Just 15 years ago, Gleevac (imatinib) changed chronic myeloid leukemia (CML) from a fatal disease to a treatable illness.

Monoclonal Antibody Is a New Option for Patients With Multiple Myeloma

Monoclonal Antibody Is a New Option for Patients With Multiple Myeloma

By

What is the new drug called Empliciti and how does it differ from other drugs used to treat multiple myeloma?

Experts' Viewpoint Offers a Salve for Skyrocketing Cancer Drug Prices

Experts' Viewpoint Offers a Salve for Skyrocketing Cancer Drug Prices

By

Oncology drug costs continue to rise, and the financial distress patients experience has led many to call for efforts to reduce oncology drug prices. Viable policy interventions will not be free and will involve tradeoffs, according to a team of experts.

Weekly Paclitaxel Doesn't Increase Survival in Ovarian Cancer

Weekly Paclitaxel Doesn't Increase Survival in Ovarian Cancer

Paclitaxel administered with carboplatin on a weekly basis is not associated with improved progression-free survival.

Implantable Device Delivers Anticancer Regimen Directly Into Pancreatic Cancer Tumors

By

An implantable device allows large doses of highly toxic drugs to be delivered directly to pancreatic tumors while reducing exposure to the toxic side effects in the rest of the body.

Antibiotics and Cardiac Glycosides May Be Effective Cancer Treatments

By

Medications normally used to treat infections and heart conditions are promising cancer treatments. These drugs were previously not known to have roles in modifying cellular epigenetics.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs